Health-related quality of life in ovarian cancer patients and its impact on clinical management

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 4, 2011, Pages 421-431

  Chase, Dana M ^a   Wenzel, Lari ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

clinical trials; ovarian cancer; quality of life; symptom management

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; HYDROCORTISONE; N TERT BUTYLNITRONE; PACLITAXEL; PYRIDOXINE; SCAVENGER; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ACUPUNCTURE; BLOATING; BLOOD TOXICITY; CANCER FATIGUE; CANCER GRADING; CANCER PAIN; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DISEASE ASSOCIATION; DRUG RESPONSE; DYSESTHESIA; DYSPNEA; EARLY DIAGNOSIS; FEMALE SEXUAL DYSFUNCTION; HIGH RISK POPULATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUROPATHIC PAIN; NEUROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PAIN; PARACENTESIS; PARESTHESIA; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); OVARIAN NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 80051721942     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.41     Document Type: Review

References (69)

1. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society, Atlanta, GA, USA (2010).
2. von Gruenigen VE, Huang HQ, Gil KM et al. A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. J. Pain Symptom Manage. 39(5), 839-846 (2010).
3. Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J. Natl Cancer Inst. 96(14), 1083-1094 (2004). (Pubitemid 39172410)
4. Madalinska JB, Hollenstein J, Bleiker E et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J. Clin. Oncol. 23(28), 6890-6898 (2005).
5. Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol. Oncol. 112(3), 594-600 (2009).
6. Kauff ND, Hurley KE, Hensley ML et al. Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. Cancer 104(2), 314-320 (2005). (Pubitemid 40993258)
7. Greene MH, Piedmonte M, Alberts D et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol. Biomarkers Prev. 17(3), 594-604 (2008 (Pubitemid 351469209)
8. Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 23(24), 5605-5612 (2005).
9. Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol. Oncol. 108(1), 100-105 (2008). (Pubitemid 350299429)
10. Wenzel LB, Huang HQ, Armstrong DK et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25(4), 437-443 (2007). (Pubitemid 350002993)
11. Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363(10), 943-953 (2010).
12. Greimel ER, Bjelic-Radisic V, Pfisterer J et al. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/ paclitaxel versus carboplatin/paclitaxel. J. Clin. Oncol. 24(4), 579-586 (2006). (Pubitemid 46630419)
13. Greimel ER, Bjelic-Radisic V, Pfisterer J et al. Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support. Care Cancer DOI: 10.1007/s00520-010-0969-8 (2010) (Epub ahead of print).
14. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28(20), 3323-3329 (2010).
15. Sehouli J, Stengel D, Oskay-Oezcelik G et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a Phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol. 26(19), 3176-3182 (2008).
16. Rustin G, van der Burg M, Griffin C, Qian W, Swart AM. Early versus delayed treatment of relapsed ovarian cancer. Lancet 377(9763), 380-381 (2011).
17. Greimel E, Daghofer F, Petru E. Prospective assessment of quality of life in long-term ovarian cancer survivors. Int. J. Cancer 128(12), 3005-3011 (2011).
18. Gotay CC, Kawamoto CT, Bottomley A et al. The prognostic significance of patient reported outcomes in cancer clinical trials. J. Clin. Oncol. 26, 1355-1363 (2008).
19. Jean-Pierre P, Figueroa-Moseley CD, Kohli S, Fiscella K, Palesh OG, Morrow GR. Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12(Suppl. 1), 11-21 (2007).
20. Kearney N, Miller M, Maguire R et al. WISECARE+: results of a European study of a nursing intervention for the management of chemotherapy-related symptoms. Eur. J. Oncol. Nurs. 12(5), 443-448 (2008).
21. Butt Z, Rosenbloom SK, Abernethy AP et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J. Natl Compr. Canc. Netw. 6(5), 448-455 (2008). (Pubitemid 351754243)
22. Holzner B, Kemmler G, Meraner V et al. Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 97(6), 1564-1572 (2003). (Pubitemid 36297787)
23. Mirabeau-Beale KL, Kornblith AB, Penson RT et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol. Oncol. 114(2), 353-359 (2009).
24. Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann. Oncol. 20(1), 17-25 (2009).
25. Luckett T, King MT. Choosing patient-reported outcome measures for cancer clinical research - practical principles and an algorithm to assist non-specialist researchers. Eur. J. Cancer 46(18), 3149-3157 (2010).
26. Matulonis UA, Kornblith A, Lee H et al. Long-term adjustment of early-stage ovarian cancer survivors. Int. J. Gynecol. Cancer 18(6), 1183-1193 (2008).
27. Traeger L, Braun IM, Greer JA, Temel JS, Cashavelly B, Pirl WF. Parsing depression from fatigue in patients with cancer using the fatigue symptom inventory. J. Pain Symptom Manage. 42(1), 52-59 (2011).
28. Weinrib AZ, Sephton SE, Degeest K et al Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer 116(18), 4410-4419 (2010).
29. Banasik J, Williams H, Haberman M, Blank SE, Bendel R. Effect of Iyengar yoga practice on fatigue and diurnal salivary cortisol concentration in breast cancer survivors. J. Am. Acad. Nurse Pract. 23(3), 135-142 (2011).
30. Dean-Clower E, Doherty-Gilman AM, Keshaviah A et al. Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients. Integr. Cancer Ther. 9(2), 158-167 (2010).
31. Stevinson C, Steed H, Faught W et al. Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning. Int. J. Gynecol. Cancer 19(1), 73-78 (2009).
32. Danhauer SC, Tooze JA, Farmer DF et al. Restorative yoga for women with ovarian or breast cancer: findings from a pilot study. J. Soc. Integr. Oncol. 6(2), 47-58 (2008). (Pubitemid 351930972)
33. Mustian KM, Morrow GR, Carroll JK, Figueroa-Moseley CD, Jean-Pierre P, Williams GC. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist 12(Suppl. 1), 52-67 (2007).
34. Gibson F, Aldiss S, Taylor RM, Maguire R, Kearney N. Involving health professionals in the development of an advanced symptom management system for young people: the ASyMS-YG study. Eur. J. Oncol. Nurs. 13(3), 187-192 (2009).
35. McCann L, Maguire R, Miller M, Kearney N. Patients' perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity. Eur. J. Cancer Care 18(2), 156-164 (2009).
36. Wenzel L, Huang HQ, Cella D, Walker JL, Armstrong DK, Gynecologic Oncology Group. Validation of FACT/ GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. Gynecol. Oncol. 110(1), 60-64 (2008).
37. Husain A, Bezjak A, Easson A. Malignant ascites symptom cluster in patients referred for paracentesis. Ann. Surg. Oncol. 17(2), 461-469 (2010).
38. Easson AM, Bezjak A, Ross S, Wright JG. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann. Surg. Oncol. 14(8), 2348-2357 (2007). (Pubitemid 47174909)
39. Keen A, Fitzgerald D, Bryant A, Dickinson HO. Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst. Rev. 20(1), CD007794 (2010).
40. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol. Oncol. 111(3), 530-532 (2008).
41. von Gruenigen VE, Huang HQ, Gil KM et al. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer 115(20), 4857-4864 (2009).
42. Havrilesky LJ, Broadwater G, Davis DM et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol. Oncol. 113(2), 216-220 (2009).
43. Bezjak A, Tu D, Bacon M et al. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J. Clin. Oncol. 22(22), 4595-4603 (2004). (Pubitemid 41185127)
44. Stewart DE, Wong F, Duff S, Melancon CH, Cheung AM. 'What doesn't kill you makes you stronger': an ovarian cancer survivor survey. Gynecol. Oncol. 83(3), 537-542 (2001). (Pubitemid 33139716)
45. Fitch MI, Gray RE, Franssen E. Women's perspectives regarding the impact of ovarian cancer: implications for nursing. Cancer Nurs. 23(5), 359-366 (2000).
46. Portenoy RK, Kornblith AB, Wong G et al. Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. Cancer 74(3), 907-915 (1994). (Pubitemid 24237472)
47. Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am. J. Ther. 17(2), 148-158 (2010).
48. Pignata S, De Placido S, Biamonte R et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 6, 5 (2006).
49. Cavaletti G, Bogliun G, Marzorati L et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann. Oncol. 15(9), 1439-1442 (2004). (Pubitemid 39295034)
50. Calhoun EA, Welshman EE, Chang CH et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group - Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int. J. Gynecol. Cancer 13, 741-748 (2003). (Pubitemid 38235217)
51. Albers J, Chaudhry V, Cavaletti G et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst. Rev. CD005228 (2007).
52. Hilpert F, Stähle A, Tomé O et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy - a double-blind, placebo-controlled, randomized Phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Support. Care Cancer 13(10), 797-805 (2005). (Pubitemid 41414020)
53. Argyriou, AA, Chroni E, Koutras A et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support. Care Cancer 14(11), 1134-1140 (2006). (Pubitemid 44898796)
54. Argyriou, AA, Chroni E, Koutras A et al. vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64(1), 26-31 (2005). (Pubitemid 40082932)
55. Kim HK, Zhang YP, Gwak YS, Abdi S. Phenyl N-tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats. Anesthesiology 112(2), 432-439 (2010).
56. Garg MB, Ackland SP. Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect. Cancer Chemother. Pharmacol. 67(4), 963-966 (2011).
57. Reis N, Beji NK, Coskun A. Quality of life and sexual functioning in gynecological cancer patients: results from quantitative and qualitative data. Eur. J. Oncol. Nurs. 14(2), 137-146 (2010).
58. Carter J, Chi DS, Brown CL et al. Cancer-related infertility in survivorship. Int. J. Gynecol. Cancer 20(1), 2-8 (2010).
59. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J. Clin. Oncol. 26(5), 753-758 (2008). (Pubitemid 351264388)
60. Gershenson DM, Miller AM, Champion VL et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25(19), 2792-2797 (2007). (Pubitemid 47123188)
61. Sabbatini P, Spriggs D, Aghajanian C et al. Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecol. Oncol. 116(1), 66-71 (2010).
62. du Bois A, Herrstedt J, Hardy-Bessard AC et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J. Clin. Oncol. 28(27), 4162-4169 (2010).
63. Pfisterer J, Weber B, Reuss A et al. Randomized Phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl Cancer Inst. 98(15), 1036-1045 (2006). (Pubitemid 44288151)
64. du Bois A, Weber B, Rochon J et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J. Clin. Oncol. 24(7), 1127-1135 (2006). (Pubitemid 46638810)
65. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel- carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 96(22), 1682-1691 (2004). (Pubitemid 39585637)
66. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol. 26(6), 890-896 (2008). (Pubitemid 351398081)
67. Mutch DG, Orlando M, Goss T et al. Randomized Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 25(19), 2811-2818 (2007). (Pubitemid 47123191)
68. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24(29), 4699-4707 (2006). (Pubitemid 46630933)
69. NIH PROMIS initiative www.nihpromis.org